We conducted a biomarker-driven trial of selumetinib (KOSELUGOTM; ARRY-142886), an orally active, allosteric mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, in pancreas cancer patients with somatic KRASG12R mutations. Here, MAP3K1 is linked to pancreatic neoplasm.